Overview

Pemigatinib was a regulatory landmark as the first targeted therapy approved for cholangiocarcinoma. Its path to market illustrates how a companion diagnostic and an accelerated approval can bring a precision therapy to a disease with few options. For buyers and clinicians, the regulatory history also defines exactly who is eligible.

The Accelerated Approval Pathway

The US FDA granted accelerated approval to pemigatinib in April 2020 for previously treated, unresectable locally advanced or metastatic cholangiocarcinoma harboring an FGFR2 fusion or other rearrangement. The basis was overall response rate and duration of response from the FIGHT-202 study, a single-arm trial, rather than a confirmed survival benefit. Continued approval remains contingent on verification in confirmatory trials.

The Mandatory Companion Diagnostic

A defining feature of the indication is that it is tied to a test. Pemigatinib is indicated only when an FGFR2 fusion or rearrangement is detected by an FDA-approved test, with FoundationOne CDx serving as the approved companion diagnostic. This linkage means reimbursement, prescribing, and procurement must all assume upfront molecular testing rather than empirical use.

Dosing and Presentation

The recommended regimen is 13.5 mg taken orally once daily for 14 days followed by 7 days off, repeated in 21-day cycles. The medicine is supplied as tablets of 4.5 mg, 9 mg, and 13.5 mg, allowing dose adjustments. The 21-capsule pack offered here supports the cycle-based schedule used in clinical practice.

What Confirmatory Evidence Still Must Show

Accelerated approval based on response rate places a standing obligation to confirm that the benefit translates into longer survival or durable symptomatic improvement. Post-marketing studies are designed to provide that evidence, and the indication could change depending on their results. For procurement and formulary planning, this means monitoring the evolving label rather than assuming the current indication is permanent. Internationally, the approved companion diagnostic and the approval status can differ, so local regulatory confirmation remains essential before adoption in a new market.

FAQ

Q: Why is a companion diagnostic required before prescribing? A: The approval is restricted to tumors with an FGFR2 fusion or rearrangement identified by an FDA-approved test, so testing is a precondition for use.

Q: Is pemigatinib approved everywhere for this indication? A: It is approved in major markets including the United States and European Union, but local labeling and reimbursement rules should always be confirmed.

Q: What does accelerated approval mean for prescribers? A: It means the benefit was established on response and duration of response, with continued approval depending on ongoing confirmatory evidence.